Provention Bio, Inc.
- Jurisdiction
United States - LEI
5493003LM26XAVJKLD34 - ISIN
US74374N1028 (PRVB )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€11.06M - Gross margin
96.0% - EBIT
-€109.96M - EBIT margin
-993.9% - Net income
-€96.93M - Net margin
-876.1%
Statement period: - (published )
Dividends
No dividend payouts
Products
Product | Revenue | |
---|---|---|
Collaboration Revenues |
| |
Product |
|
Earnings Calls
Latest earnings call: November 3, 2022